Patent intelligence · US
US 11026905
STAT3 inhibitors
STAT3 inhibitors
Patent details — US 11026905
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jun 8, 2021
- Expiration
- Jun 3, 2041
- Applicant
- Tvardi Therapeutics, Inc.
- Claims
- 6
- CPC classes
- A61K, A61K31/18
Quick answer
US 11026905 (STAT3 inhibitors) is held by Tvardi Therapeutics, Inc.. Status: granted. Granted Jun 8, 2021. Expires Jun 3, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Tvardi Therapeutics, Inc.
- Grant date
- Expiration
- Claims
- 6
- CPC classes
- A61K, A61K31/18
More from Tvardi Therapeutics, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12053444
Therapeutic compounds, formulations, and uses thereof
granted -
US 12043640
Prodrugs of STAT3 inhibitors
granted -
US 11826315
STAT3 inhibitors
granted -
US 11547683
Therapeutic compounds, formulations, and uses thereof
granted -
US 11077077
Therapeutic compounds, formulations, and uses thereof
granted
Frequently asked questions
What is US patent 11026905?
US 11026905 (STAT3 inhibitors) is held by Tvardi Therapeutics, Inc.. Status: granted. Granted Jun 8, 2021. Expires Jun 3, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11026905?
Tvardi Therapeutics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 6 pharmaceutical patents for this assignee.
When does US 11026905 expire?
Our index shows an expiration date of Jun 3, 2041 (15 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.